Mode
Text Size
Log in / Sign up
N/A Completed N=10 Randomized Double-blind Treatment

Clinical Evaluation of Invigor Toric 1-Day Contact Lenses

Astigmatism
Source: ClinicalTrials.gov NCT04016623 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Visibility of Toric Mark — 100; 100; 0; 0 percentage of participants

Summary

An evaluation of the clinical performance of the 1-day toric test contact lens compared to the 1-day toric control contact lens over one hour of lens wear.

Outcome Measures

OutcomeResultp-value
PRIMARY
Visibility of Toric Mark
100; 100; 0; 0
PRIMARY
Degree of Lens Orientation
-1; -1
PRIMARY
Toric Stability
5; 4
PRIMARY
Degree of Rotational Recovery
16; 12; 9; 10
PRIMARY
Toric Fit Acceptance
3.5; 3.4
PRIMARY
Toric Fit Preference
33; 57; 10
SECONDARY
Measurement of Lens Horizontal Centration
-0.06; -0.08
SECONDARY
Measurement of Lens Vertical Centration
0.32; 0.27
SECONDARY
Measurement of Lens Movement
0.25; 0.24
SECONDARY
Lens Push-Up
47; 47
SECONDARY
Primary Lens Gaze Lag
0.20; 0.19
SECONDARY
General Lens Fit Acceptance
3.4; 3.4
SECONDARY
Up Gaze Lag
0.22; 0.22
SECONDARY
General Lens Fit Preference
3; 94; 3

Eligibility Criteria

Inclusion Criteria

  • Has had a self-reported oculo-visual examination in the last two years.
  • Is at least 18 years of age and has full legal capacity to volunteer.
  • Has read and understood the information consent letter.
  • Is willing and able to follow instructions and maintain the appointment schedule.
  • Is correctable to a visual acuity of 20/40 or better (in each eye) with their habitual vision correction or 20/20 best-corrected.
  • Currently wears soft contact lenses.
  • Has clear corneas and no active ocular disease.
  • Has not worn lenses for at least 12 hours before the examination

Exclusion Criteria

  • Has never worn contact lenses before.
  • Has any systemic disease affecting ocular health.
  • Is using any systemic or topical medications that will affect ocular health.
  • Has any ocular pathology or severe insufficiency of lacrimal secretion (moderate to severe dry eyes) that would affect the wearing of contact lenses.
  • Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye.
  • Has any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars.
  • Is aphakic.
  • Has undergone corneal refractive surgery.
  • Is participating in any other type of eye related clinical or research study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04016623). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search